Gilead Sciences has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for remdesivir to treat Covid-19 infection.
The authorisation is set to allow broader access to remdesivir for treating hospitalised patients with severe Covid-19 across the US.
Gilead will work with the government to allocate the currently limited supply of the drug. Gilead Sciences chairman and CEO Daniel O’Day said: “This EUA opens the way for us to provide emergency use of remdesivir to more patients with severe symptoms of Covid-19. “We will continue to work with partners across the globe to increase our supply of remdesivir while advancing our ongoing clinical trials to supplement our understanding of the drug’s profile.”
Read more on pharmaceutical-technology.com